RxDoctor Payments Data

David Verbofsky, MD

Internal Medicine · Philadelphia, PANPI 1043504871

Payments from drug & device makers

$1,862in general payments, 2019–2025

Across 92 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$324
  • AbbVie$290
  • Novo Nordisk$262
  • Gilead$216
  • Pfizer$172
  • Inspire Medical Systems, Inc.$127
  • plus $470 from 13 others

What the payments were for

  • Food & beverage$1,861100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,862 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$85,538
Medicare patients
207
Services billed
1,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$87,455
MounjaroTirzepatide28$35,073
XareltoRivaroxaban25$33,683
OzempicSemaglutide14$14,826
AdderallDextroamphetamine/Amphetamine12$7,556
GlyxambiEmpagliflozin/Linagliptin12$6,756
VascepaIcosapent Ethyl11$3,834
Atorvastatin Calcium233$3,104
Rosuvastatin Calcium219$2,908
PaxlovidNirmatrelvir/Ritonavir18$2,858
Tamsulosin Hcl108$2,405
Testosterone12$2,309
Valsartan64$2,200
SynthroidLevothyroxine Sodium29$2,185
Levothyroxine Sodium126$1,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$172$90,31385 claims
Lilly USA, LLCMounjaro$78$35,07328 claims
Johnson & JohnsonXarelto$38$33,68325 claims
Novo NordiskOzempic$262$14,82614 claims
Boehringer IngelheimGlyxambi$61$6,75612 claims
AbbVieSynthroid$290$2,18529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →